Negative regulation of the oncogenic transcription factor FoxM1 by thiazolidinediones and mithramycin
暂无分享,去创建一个
A. Tyner | L. Lau | R. Costa | P. Raychaudhuri | V. Petrovic
[1] M. Maa,et al. Mithramycin inhibits human epithelial carcinoma cell proliferation and migration involving downregulation of Eps8 expression. , 2010, Chemico-biological interactions.
[2] A. Barsotti,et al. Pro-proliferative FoxM1 is a target of p53-mediated repression , 2009, Oncogene.
[3] A. Gartel,et al. p53 negatively regulates expression of FoxM1 , 2009, Cell cycle.
[4] N. Hay,et al. FoxM1, a critical regulator of oxidative stress during oncogenesis , 2009, The EMBO journal.
[5] J. Asara,et al. A Conserved Phosphorylation Site within the Forkhead Domain of FoxM1B Is Required for Its Activation by Cyclin-CDK1* , 2009, The Journal of Biological Chemistry.
[6] A. Gartel,et al. A novel mode of FoxM1 regulation: Positive auto-regulatory loop , 2009, Cell cycle.
[7] A. Gartel,et al. Thiazole Antibiotics Target FoxM1 and Induce Apoptosis in Human Cancer Cells , 2009, PloS one.
[8] Su-Lin Lee,et al. PPARgamma-independent antitumor effects of thiazolidinediones. , 2009, Cancer letters.
[9] Sridhar Hannenhalli,et al. The evolution of Fox genes and their role in development and disease , 2009, Nature Reviews Genetics.
[10] F. Ondrey,et al. Peroxisome Proliferator-Activated Receptor γ Pathway Targeting in Carcinogenesis: Implications for Chemoprevention , 2009, Clinical Cancer Research.
[11] B. Necela,et al. Peroxisome Proliferator-activated Receptor γ Down-regulates Follistatin in Intestinal Epithelial Cells through SP1* , 2008, Journal of Biological Chemistry.
[12] A. Tyner,et al. FoxM1 Regulates Transcription of JNK1 to Promote the G1/S Transition and Tumor Cell Invasiveness* , 2008, Journal of Biological Chemistry.
[13] I. Wierstra,et al. Sp1: emerging roles--beyond constitutive activation of TATA-less housekeeping genes. , 2008, Biochemical and biophysical research communications.
[14] M. Tretiakova,et al. Transgenic expression of the forkhead box M1 transcription factor induces formation of lung tumors , 2008, Oncogene.
[15] B. Woda,et al. Sp1, a New Biomarker That Identifies a Subset of Aggressive Pancreatic Ductal Adenocarcinoma , 2008, Cancer Epidemiology Biomarkers & Prevention.
[16] W. Hung,et al. Overexpression of Jab1 in Hepatocellular Carcinoma and Its Inhibition by Peroxisome Proliferator-Activated Receptorγ Ligands In vitro and In vivo , 2008, Clinical Cancer Research.
[17] Jun Zhang,et al. Targeted inhibition of Sp1-mediated transcription for antiangiogenic therapy of metastatic human gastric cancer in orthotopic nude mouse models. , 2008, International journal of oncology.
[18] J. Roman. Peroxisome Proliferator-Activated Receptor &ggr; and Lung Cancer Biology: Implications for Therapy , 2008, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.
[19] A. Tyner,et al. FoxM1 Regulates Growth Factor-induced Expression of Kinase-interacting Stathmin (KIS) to Promote Cell Cycle Progression* , 2008, Journal of Biological Chemistry.
[20] Ole Winther,et al. JASPAR, the open access database of transcription factor-binding profiles: new content and tools in the 2008 update , 2007, Nucleic Acids Res..
[21] A. Gartel. FoxM1 inhibitors as potential anticancer drugs. , 2008, Expert opinion on therapeutic targets.
[22] Huamin Wang,et al. Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer , 2007, Cancer.
[23] I. Wierstra,et al. FOXM1, a typical proliferation-associated transcription factor , 2007, Biological chemistry.
[24] Jun Zhang,et al. Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A. , 2007, Cancer research.
[25] C. Chen,et al. Peroxisome proliferator-activated receptor gamma-independent suppression of androgen receptor expression by troglitazone mechanism and pharmacologic exploitation. , 2007, Cancer research.
[26] N. Davidson,et al. The forkhead box M1 transcription factor contributes to the development and growth of mouse colorectal cancer. , 2007, Gastroenterology.
[27] G. Adami,et al. Future roles for FoxM1 inhibitors in cancer treatments. , 2007, Future oncology.
[28] René H Medema,et al. FoxM1: at the crossroads of ageing and cancer. , 2007, Biochimica et biophysica acta.
[29] A. Scheen. Pharmacokinetic Interactions with Thiazolidinediones , 2007, Clinical pharmacokinetics.
[30] Tae-Jin Lee,et al. Mithramycin A sensitizes cancer cells to TRAIL-mediated apoptosis by down-regulation of XIAP gene promoter through Sp1 sites , 2006, Molecular Cancer Therapeutics.
[31] J. Blaydes,et al. GC-selective DNA-binding antibiotic, Mithramycin A, reveals multiple points of control in the regulation of Hdm2 protein synthesis , 2006, Oncogene.
[32] C.-S. Chen,et al. Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones. , 2006, Endocrine-related cancer.
[33] Aklank Jain,et al. Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy , 2006, Nucleic acids research.
[34] M. Tretiakova,et al. The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. , 2006, Cancer research.
[35] R. Costa,et al. Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice. , 2006, Cancer research.
[36] P. Malfertheiner,et al. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo , 2006, Hepatology.
[37] Vladimir Petrovic,et al. Forkhead Box M1 Regulates the Transcriptional Network of Genes Essential for Mitotic Progression and Genes Encoding the SCF (Skp2-Cks1) Ubiquitin Ligase , 2005, Molecular and Cellular Biology.
[38] Bingya Liu,et al. Transcription factor Sp1 expression in gastric cancer and its relationship to long-term prognosis. , 2005, World journal of gastroenterology.
[39] R. Costa. FoxM1 dances with mitosis , 2005, Nature Cell Biology.
[40] A. Gartel,et al. The PPAR-? Agonist Pioglitazone Post-Trancriptionally Induces p21 in PC3 Prostate Cancer but Not in Other Cell Lines , 2005, Cell cycle.
[41] C. Pilarsky,et al. Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. , 2004, Neoplasia.
[42] Lance D. Miller,et al. BEARR: Batch Extraction and Analysis of cis-Regulatory Regions , 2004, Nucleic Acids Res..
[43] Tsung-Teh Wu,et al. Association between Expression of Transcription Factor Sp1 and Increased Vascular Endothelial Growth Factor Expression, Advanced Stage, and Poor Survival in Patients with Resected Gastric Cancer , 2004, Clinical Cancer Research.
[44] Robert H. Costa,et al. Forkhead Box M1B Transcriptional Activity Requires Binding of Cdk-Cyclin Complexes for Phosphorylation-Dependent Recruitment of p300/CBP Coactivators , 2004, Molecular and Cellular Biology.
[45] A. Datta,et al. Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. , 2004, Genes & development.
[46] C. Grommes,et al. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. , 2004, The Lancet. Oncology.
[47] J. Ajani,et al. Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[48] M. Harada,et al. Troglitazone induces p27Kip1‐associated cell‐cycle arrest through down‐regulating Skp2 in human hepatoma cells , 2003, Hepatology.
[49] J. Sahi,et al. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[50] S. Baek,et al. Troglitazone, a Peroxisome Proliferator-activated Receptor γ (PPARγ) Ligand, Selectively Induces the Early Growth Response-1 Gene Independently of PPARγ , 2003, The Journal of Biological Chemistry.
[51] B. Song,et al. Critical role of c-Jun N-terminal protein kinase activation in troglitazone-induced apoptosis of human HepG2 hepatoma cells. , 2003, Molecular pharmacology.
[52] S. Baek,et al. Troglitazone, a peroxisome proliferator-activated receptor gamma (PPAR gamma ) ligand, selectively induces the early growth response-1 gene independently of PPAR gamma. A novel mechanism for its anti-tumorigenic activity. , 2003, The Journal of biological chemistry.
[53] T. Okumura,et al. Troglitazone Induces G1 Arrest by p27Kip1 Induction That Is Mediated by Inhibition of Proteasome in Human Gastric Cancer Cells , 2002, Japanese journal of cancer research : Gann.
[54] P. Farnham,et al. Characterizing transcription factor binding sites using formaldehyde crosslinking and immunoprecipitation. , 2002, Methods.
[55] W. Hsueh,et al. Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators. , 2001, Biochemical and biophysical research communications.
[56] A. Werner,et al. A Review of Rosiglitazone in Type 2 Diabetes Mellitus , 2001, Pharmacotherapy.
[57] J. Black,et al. Sp1 and krüppel‐like factor family of transcription factors in cell growth regulation and cancer , 2001, Journal of cellular physiology.
[58] T. Kawaguchi,et al. Involvement of p21WAF1/Cip1, p27Kip1, and p18INK4c in troglitazone‐induced cell‐cycle arrest in human hepatoma cell lines , 2001 .
[59] T. Kawaguchi,et al. Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. , 2001, Hepatology.
[60] T. Okura,et al. Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells. , 2000, European journal of pharmacology.
[61] R. Costa,et al. Premature Expression of the Winged Helix Transcription Factor HFH-11B in Regenerating Mouse Liver Accelerates Hepatocyte Entry into S Phase , 1999, Molecular and Cellular Biology.
[62] M. Henriksson,et al. Interaction of the fork head domain transcription factor MPP2 with the human papilloma virus 16 E7 protein: enhancement of transformation and transactivation , 1999, Oncogene.
[63] E. Randinitis,et al. Clinical Pharmacokinetics of Troglitazone , 1999, Clinical pharmacokinetics.
[64] J. Lehmann,et al. The PPARs and PXRs: nuclear xenobiotic receptors that define novel hormone signaling pathways. , 1999, Recent progress in hormone research.
[65] Samuel Singer,et al. Differentiation and reversal of malignant changes in colon cancer through PPARγ , 1998, Nature Medicine.
[66] H P Koeffler,et al. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. , 1998, Cancer research.
[67] H. Clevers,et al. The human TRIDENT/HFH-11/FKHL16 gene: structure, localization, and promoter characterization. , 1997, Genomics.
[68] H. Clevers,et al. The winged-helix transcription factor Trident is expressed in cycling cells. , 1997, Nucleic acids research.
[69] L. Lim,et al. Hepatocyte Nuclear Factor 3 / fork head Homolog 11 Is Expressed in Proliferating Epithelial and Mesenchymal Cells of Embryonic and Adult Tissues , 1996 .
[70] Eric F. Johnson,et al. Novel Sequence Determinants in Peroxisome Proliferator Signaling (*) , 1995, The Journal of Biological Chemistry.
[71] R. Snyder,et al. Triplex formation prevents Sp1 binding to the dihydrofolate reductase promoter. , 1992, The Journal of biological chemistry.